RE: LeoThread 2025-12-22 23-06

• Science basics: Traces back to 1950s mouse studies; exchanging old blood for younger blood appears to rejuvenate organs by diluting age-related factors.

Human trials since 2016 showed lowered aging biomarkers in older adults, but no proven lifespan extension

• Wealthy patrons: Some billionaires such as Peter Thiel and Bryan Johnson have funded or experimented with the approach, including family plasma exchanges reported in 2023. Price estimates range from $8K to $2M per session

• China’s surge and scandals: China has led clinical activity since the 2010s, with clinics charging $10K+ for so-called “youth plasma.” A 2025 controversy involved billionaire Yu Wenhong receiving a reported $2.8M therapy sourced from young men’s blood, sparking outrage over sourcing and inequality

• Ethics and risks: Regulators like the FDA warn the practice is unproven and potentially dangerous, with concerns about exploitation of donors. Synthetic protein alternatives are under development

Human trafficking fears

The controversy around young-blood therapies in China—including reports of $2.8M injections made from plasma of 17–21-year-old men—has raised alarms about a possible trade that coerces or economically pressures vulnerable youth.

Leaked footage and investigative reports suggest opaque supply chains that could involve forced recruitment or exploitation, and a 2025 U.S.

State Department report highlights abuse patterns, such as forced labor, that might spill into alternative-medicine markets. The pursuit of “eternal youth” risks becoming a pathway to human exploitation